Clinical Trial: Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?

Brief Summary: Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.

Detailed Summary:
Sponsor: A. D. Struthers

Current Primary Outcome: Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients [ Time Frame: 9 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Secondary objective is to see if Allopurinol reduces endothelial dysfunction in this group of CKD patients [ Time Frame: 9 months ]

Original Secondary Outcome: Same as current

Information By: University of Dundee

Dates:
Date Received: May 29, 2008
Date Started: January 2008
Date Completion:
Last Updated: November 2, 2016
Last Verified: November 2016